Barostim and the Window of Opportunity in Class II/III HFrEF Patients THT 2024 Discussion

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

10 seconds

Playback speed

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

Barostim and the Window of Opportunity in Class II/III HFrEF Patients THT 2024 Discussion

By CVRx | Barostim FEATURING Gurusher Panjrath, Dmitry Yaranov, JoAnn Lindenfeld, J. Thomas Heywood

147 views

April 24, 2024

Hear discussion and insights from Drs. J. Thomas Heywood, JoAnn Lindenfeld, Gurusher Panjrath, and Dmitry Yaranov following the THT 2024 symposium.

Comments 0

Real-World Results with Barostim within a Multi-Disciplinary Heart F…

Feat. P. Mccann

Outsmarting the Heart: Device Therapy Targeting the Neurohormonal Pa…

Feat. M. Fudim, D. Yaranov, R. C. Mohan, P. Mccann, R. Gupta